Dosing dilemmas in obese children

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Archives of Disease in Childhood: Education & Practice Edition

• Publication date

  2010-06-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/adc.2009.163055PMID 20585055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population-Based Pharmacokinetic Modeling and Simulation

  2012cited by this paper
• Adjustment of dosing of antimicrobial agents for bodyweight in adults.

  2010cited by this paper
• Effect of Obesity on the Pharmacokinetics of Drugs in Humans

  2010cited by this paper
• A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.

  2009cited by this paper
• Response to “Influence of Lean Body Weight on Anticancer Drug Clearance”

  2009cited by this paper
• Rise in obesity among children in England may be slowing

  2009cited by this paper
• Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).

  2009cited by this paper
• Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study

  2009cited by this paper
• Encouraging the Move Towards Predictive Population Models for the Obese Using Propofol as a Motivating Example

  2009cited by this paper
• Influence of Lean Body Weight on Anticancer Drug Clearance

  2009cited by this paper
• Comorbidities of overweight/obesity experienced in adolescence: longitudinal study

  2009cited by this paper
• Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method.

  2009cited by this paper
• Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study.

  2007cited by this paper
• Ideal body weight in children.

  2007cited by this paper
• Dosing in Obesity: A Simple Solution to a Big Problem

  2007cited by this paper
• Body composition in normal weight, overweight and obese children: matched case–control analyses of total and regional tissue masses, and body composition trends in relation to relative weight

  2006cited by this paper
• Quantification of Lean Bodyweight

  2005cited by this paper
• COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON THE EVALUATION OF THE PHARMACOKINETICS OF MEDICINAL PRODUCTS IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION

  2005cited by this paper
• Human physiologically based pharmacokinetic model for propofol

  2005influential reference
• Climate change and recent genetic flux in populations of Drosophila robusta

  2005cited by this paper
• What is the best size descriptor to use for pharmacokinetic studies in the obese?

  2004cited by this paper
• The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics

  2004cited by this paper
• Accepted after revision:

  2004cited by this paper
• Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.

  2003influential reference
• Which weight for weight-based dosage regimens in obese patients?

  2002cited by this paper
• Basic anatomical and physiological data for use in radiological protection: reference values

  2002cited by this paper
• The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers

  2002cited by this paper
• Changes in plasma protein binding have little clinical relevance

  2002cited by this paper
• Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing

  2001cited by this paper
• Functional and structural changes in the kidney in the early stages of obesity.

  2001cited by this paper
• Effects of obesity on pharmacokinetics implications for drug therapy.

  2000cited by this paper
• Pharmacokinetics of rocuronium bromide in obese female patients.

  1999cited by this paper
• Vancomycin dosing in morbidly obese patients

  1998cited by this paper
• Health consequences of obesity in youth: childhood predictors of adult disease.

  1998cited by this paper
• Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.

  1997cited by this paper
• Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers

  1997cited by this paper
• Population pharmacokinetics of total and unbound etoposide

  1997cited by this paper
• Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.

  1996cited by this paper
• Carbamazepine Phakmacokinetics in Obese and Lean Subjects

  1995cited by this paper
• Caffeine pharmacokinetics in obesity and following significant weight reduction.

  1995cited by this paper
• Aminoglycoside dosing weight correction factors for patients of various body sizes

  1995cited by this paper
• Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients.

  1994cited by this paper
• Lithium pharmacokinetics in the obese

  1994cited by this paper
• Intravenous ciprofloxacin disposition in obesity

  1993cited by this paper
• Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique

  1993cited by this paper
• Propofol Infusion for Maintenance of Anesthesia in Morbidly Obese Patients Receiving Nitrous Oxide A Clinical and Pharmacokinetic Study

  1993cited by this paper
• Pharmacokinetics of Ranitidine in Morbidly Obese Women

  1990cited by this paper
• Pharmacokinetics of ranitidine in morbidly obese women.

  1990cited by this paper
• Verapamil pharmacodynamics and disposition in obese hypertensive patients.

  1988cited by this paper
• Phenytoin disposition in obesity. Determination of loading dose.

  1985cited by this paper
• Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects.

  1984cited by this paper
• "Handbook of clinical drug data".

  1983cited by this paper
• Vancomycin pharmacokinetics in normal and morbidly obese subjects

  1982cited by this paper
• Understanding the Dose-Effect Relationship

  1981cited by this paper
• Amikacin pharmacokinetics in morbidly obese patients.

  1980cited by this paper
• Tobramycin pharmacokinetics in morbidly obese patients

  1979cited by this paper
• Research on obesity

  1977cited by this paper
• Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr.

  1967cited by this paper

• Dosing chemotherapy in children with obesity: literature review and evaluation of local practices

  2025cites this paper
• Pharmacokinetics and Childhood Obesity: Pathophysiological Basis and Challenges in Choosing the Ideal Body Size Descriptor

  2025influential citation
• [Translated article] High-risk pediatric medications: A listing proposal by interdisciplinary consensus technique.

  2025cites this paper
• Association of Obesity With Sedative Dosing, Sedative Response, and Clinical Outcomes in Mechanically Ventilated Critically Ill Children

  2025cites this paper
• Parental knowledge and attitudes about the impact of childhood obesity on perioperative outcomes

  2025cites this paper
• High-risk pediatric medications: A listing proposal by interdisciplinary consensus technique.

  2024cites this paper
• High-risk pediatric medications: A listing proposal by interdisciplinary consensus technique.

  2024cites this paper
• Medication Dosing for Children With Overweight and Obesity.

  2024cites this paper
• Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD

  2023cites this paper
• Pharmacokinetics and Proposed Dosing of Levetiracetam in Children With Obesity.

  2023cites this paper
• Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney function

  2023cites this paper
• Population Pharmacokinetics of Single Bolus Dose Fentanyl in Obese Children

  2023cites this paper
• The “therapeutic” conundrum of determining accurate drug dosage in overweight and obese children

  2023cites this paper
• Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents

  2023cites this paper
• Perioperative Acetaminophen Dosing in Obese Children

  2023cites this paper
• Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice

  2022cites this paper
• Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes

  2022cites this paper
• Ibuprofen efficacy, tolerability and safety in obese children: a systematic review

  2022cites this paper
• Medication Errors in Overweight and Obese Pediatric Patients: A Narrative Review.

  2021cites this paper
• Pediatric obesity and perioperative medicine

  2021cites this paper
• Prescribing drugs to overweight and obese children: Balancing efficacy and safety.

  2021cites this paper
• Pharmacokinetic concepts for dexmedetomidine target‐controlled infusion pumps in children

  2021cites this paper
• Perioperative respiratory adverse events during ambulatory anesthesia in obese children

  2021cites this paper
• Determination of ED95 of a single-bolus dose of dexmedetomidine for adequate sedation in children and adolescents with and without obesity.

  2021cites this paper
• ANTICANCER DRUG TREATMENT IN PEDIATRIC PATIENTS: STUDIES ON OPTIMIZING DOSAGE AND ON PARENTAL GUIDANCE FOR IMPROVED DRUG HANDLING AT HOME

  2021influential citation
• Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

  2021cites this paper
• Pharmacokinetics and Pharmacodynamics in the Pediatric Population

  2021cites this paper
• Practical Challenges—Use of Paracetamol in Children and Youth Who are Overweight or Obese: A Narrative Review

  2020cites this paper
• Childhood obesity : Pharmacokinetic considerations for drugs used in the intensive care unit

  2019cites this paper
• Covariate Analysis in Clinical Anaesthesia

  2019cites this paper
• Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents

  2019cites this paper
• Overcoming the challenges of prescribing paracetamol in the overweight paediatric population

  2019cites this paper
• Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children

  2019cites this paper
• Obesidad pediátrica: consideraciones farmacocinéticas de los medicamentos utilizados en Terapia Intensiva

  2019cites this paper
• Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review

  2018cites this paper
• Anesthetic and pharmacologic considerations in perioperative care of obese children.

  2018cites this paper
• Pharmacological Prescription Dilemmas in Obese Children and Adolescents

  2018cites this paper
• Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study

  2018cites this paper
• Effect of obesity on biodistribution of nanoparticles

  2018cites this paper
• Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study

  2018influential citation
• Effect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessment

  2018cites this paper
• Dosing for Fentanyl Infusion in Obese Children: Just Because It's What We Have Always Done Doesn't Mean It Is Right.

  2018cites this paper
• Discontinuities and disruptions in drug dosage guidelines for the paediatric population

  2018cites this paper
• Estimación del peso según la edad. Comparación de las fórmulas en una muestra peruana

  2018cites this paper
• Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review

  2018cites this paper
• Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance

  2018cites this paper
• What is the best size predictor for dose in the obese child?

  2017cites this paper
• Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study

  2017cites this paper
• Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults

  2017cites this paper
• A Prospective Evaluation of the Accuracy of Weight Estimation Using the Broselow Tape in Overweight and Obese Pediatric Patients in the Emergency Department

  2017cites this paper
• The Conundrum of Optimal Drug Dosing in Obese Children.

  2017cites this paper
• Infantile Cortical Hyperostosis of Scapula Presenting as Pseudoparalysis in an Infant.

  2017cites this paper
• Medication Dosage in Overweight and Obese Children.

  2017cites this paper
• Drug Dosing in Obese Children: Challenges and Evidence-Based Strategies.

  2017cites this paper
• Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing

  2017influential citation
• A systematic review and meta-analysis of the accuracy of weight estimation systems used in paediatric emergency care in developing countries

  2017cites this paper
• Emergency weight estimation lookup tables for New Zealand children aged 5–10 years

  2016cites this paper
• The CYTONOX trial.

  2016cites this paper
• Review of commonly used age‐based weight estimates for paediatric drug dosing in relation to the pharmacokinetic properties of resuscitation drugs

  2016cites this paper
• Prescribing in obese children: how good are paediatricians?

  2016cites this paper
• Chapter 4 Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents

  2016cites this paper
• Precision Dosing in Children

  2016cites this paper
• Pharmacodynamic Considerations and Special Populations: Pediatrics

  2016cites this paper
• Paediatric drug development : an opportunity for academia to close the gap

  2016cites this paper
• Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents.

  2015cites this paper
• Prescribing for children

  2015cites this paper
• P 48 WHAT DO HOSPITAL PAEDIATRIC CLINICAL PHARMACISTS ACTUALLY DO?

  2015cites this paper
• Inter-individual variation in morphine clearance in children

  2015cites this paper
• Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents.

  2015cites this paper
• Development of recommendations for dosing of commonly prescribed medications in critically ill obese children.

  2015cites this paper
• Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.

  2015cites this paper
• Drug disposition in obesity: toward evidence-based dosing.

  2015cites this paper
• Impact of Body Habitus on Phenytoin Levels Following Fosphenytoin Loading Dose in Pediatric Patients

  2015cites this paper
• Does obesity prolong anesthesia in children undergoing common ENT surgery?

  2014cites this paper
• Ketamine dosing in adolescents: sizing up the problem.

  2014cites this paper
• Comparison of 3 body size descriptors in critically ill obese children and adolescents: implications for medication dosing.

  2014cites this paper
• Drug Dosing in Obese Patients: A Dilemma

  2014cites this paper
• Obesity in Critical Illness

  2014cites this paper
• Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings

  2014cites this paper
• The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin

  2013cites this paper
• The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin.

  2013cites this paper
• Evaluation of propofol anesthesia in morbidly obese children and adolescents

  2013cites this paper
• Understanding dosing: children are small adults, neonates are immature children

  2013cites this paper
• Overweight and Obesity

  2012cites this paper
• Challenging Ronald: McDonald versus McDonald's

  2012cites this paper
• Anesthetic Management of an Obese Child with Charcot-Marie-ToothDisease: A Case Study

  2012cites this paper
• Perceived and actual paracetamol dosing in overweight and obese children

  2012cites this paper
• Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib

  2012cites this paper
• My child is unique; the pharmacokinetics are universal

  2012cites this paper
• Propofol clearance in morbidly obese children and adolescents: influence of age and body size.

  2012cites this paper
• Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

  2012cites this paper
• Propofol Clearance in Morbidly Obese Children and Adolescents

  2012cites this paper
• Retrospective review of propofol dosing for procedural sedation in pediatric patients.

  2012cites this paper
• The Effect of Obesity on the ED95 of Propofol for Loss of Consciousness in Children and Adolescents

  2012influential citation
• Obesity and Its Impact on Drug Therapy

  2011cites this paper